What the numbers mean
Every figure on this page was observed on September 17, 2026. Prices change by place and by date. They are reported here as market observations, not as offers.
About $14 to $27
This was the observed cash or list-price range for one approved 30 mL vial. It is a range, not a promised checkout price.
About $8 to $13
This was the observed range for one vial on two sites that disclaimed human use. Neither source is named or linked here.
About $5
The federal acquisition benchmark worked out to $5.13 for a 30 mL vial. That is what pharmacies paid, not a consumer price.
Up 98.8%
The acquisition benchmark rose from $2.58 to $5.13 per vial between December 2025 and August 2026.
The observed unapproved listings cost only a few dollars less than the approved product. That small gap does not provide an approval, a full label, or a verified supply chain.
Why the label says “Rx only”
Bacteriostatic water is a prescription drug in the United States. Federal law requires the approved product to be dispensed on a licensed practitioner’s prescription.
The ordinary route is a state-licensed pharmacy. The bottle may also come with the medicine it is meant to dilute. In that case, the medicine maker has already chosen the liquid.
A listing that does not require a prescription is not an over-the-counter form of the approved medicine. FDA names that as a warning sign for an unsafe online pharmacy.
Why it can be hard to find
FDA listed the shortage as current on September 17, 2026. The record was first posted on December 3, 2021 and was last revised on September 9, 2026.
A national pharmacy shortage bulletin gave two linked reasons: manufacturing delays and a sole supplier. The bulletin said normal ordering could not be filled, while limited supply remained available.
Those words matter. A current shortage does not mean that no bottle can be found. It means the supply is too tight for usual ordering.
The sharp rise in the pharmacy acquisition benchmark happened during the same shortage. That timing is consistent with tight supply, but it does not prove that the shortage caused the price change.
Why the cheap bottle needs more checking
The unapproved market often uses “bac water” or “reconstitution solution.” It may place the water beside injectable peptides and add a “research use only” notice.
FDA warning letters show that regulators look beyond that notice. They look at how the product is described, paired, and intended to be used.
The safest useful check is not a brand recommendation. It is a record check. An approved bottle can be traced from the NDC Directory to Drugs@FDA and then to a full DailyMed label.
FDA says assignment of an NDC number does not prove approval. The application and full label provide the rest of the picture.